Positive NICE recommendation for Tegsedi

The National Institute for Health and Care Excellence (NICE) has issue a positive recommendation for Tegsedi (inotersen) for treating stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).

This decision will allow patients in England with this rare, inherited, severely debilitating and fatal disease to access the treatment on the NHS.

“This is a landmark day for people with hATTR amyloidosis who have had very limited options available to them to date,” said Carlos Heras-Palou of the UK ATTR Amyloidosis Patients Association.

“There is a critical need for innovative new therapies for people across the UK living with this debilitating disease. We hope inotersen will be available to patients in the UK very soon.”

Inotersen is an antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production. It is the first and only subcutaneous RNA-targeting drug designed to reduce the production of human transthyretin (TTR) protein.

NICE has made the final recommendations on how inotersen should be used in the NHS. The NICE decision was based on clinical trial evidence that shows inotersen slows progression of the disease considerably, although its long-term benefits are uncertain.

The recommendation is expected to form the basis for NICE’s final Technology Appraisal Guidance (TAG), the final process step before the treatment is available on the NHS in England.

Once the final guidance is published, the NHS mandate requires that inotersen is available for routine use within 90 days.

“We are delighted with this news that patients can access inotersen in England,” commented Dr. Richard A. Jones, SVP Head of Europe for Akcea Therapeutics.

“hATTR amyloidosis is a debilitating disease that, to date, has had limited treatment options in the UK.”

The decision is based on evidence from the NEURO-TTR trial, a Phase 3 randomised placebo-controlled study evaluating inotersen compared to placebo.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...

First generic remdesivir for COVID-19 treatment launched

Beximco Pharmaceuticals, the Bangladesh-based manufacturer of generic pharma products and APIs, has launched the world’s first generic remdesivir for treating COVID-19. Remdesivir is an antiviral...

Vividion Therapeutics partners with Roche on novel E3 ligases

San Diego biotech, Vividion Therapeutics, is collaborating with Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3...

Related news

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Sinovac secures $15m to accelerate COVID-19 vaccine development

Sinovac Biotech, a Chinese biopharma product provider, has secured $15 million to accelerate the development of a COVID-19 vaccine. The funds were invested by Advantech...